Compare RBKB & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RBKB | CGEN |
|---|---|---|
| Founded | 1860 | 1993 |
| Country | United States | Israel |
| Employees | 168 | N/A |
| Industry | Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 178.3M | 148.7M |
| IPO Year | 2018 | 2001 |
| Metric | RBKB | CGEN |
|---|---|---|
| Price | $16.15 | $1.86 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 17.7K | ★ 191.2K |
| Earning Date | 04-27-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.70 | N/A |
| Revenue | ★ $3,002,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $164.92 |
| P/E Ratio | $22.87 | ★ N/A |
| Revenue Growth | ★ 4.24 | N/A |
| 52 Week Low | $9.31 | $1.13 |
| 52 Week High | $16.23 | $2.38 |
| Indicator | RBKB | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 77.16 | 55.87 |
| Support Level | $11.38 | $1.47 |
| Resistance Level | N/A | $2.38 |
| Average True Range (ATR) | 0.62 | 0.09 |
| MACD | 0.14 | 0.01 |
| Stochastic Oscillator | 95.86 | 83.34 |
Rhinebeck Bancorp Inc is the holding company for Rhinebeck Bank which provides a full range of banking and financial services to consumer and commercial customers. Financial services, including investment advisory and financial product sales, are offered through a division of the Bank doing business as Rhinebeck Asset Management (RAM). The Bank's primary business activity is accepting deposits from the general public and using those funds to originate indirect automobile loans (automobile loans referred by automobile dealerships), commercial real estate loans (which include multi-family real estate loans and commercial construction loans), commercial business loans and one-to four-family residential real estate loans, and to purchase investment securities.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.